Form 8-K - Current report:
SEC Accession No. 0001558370-23-006110
Filing Date
2023-04-18
Accepted
2023-04-18 09:00:22
Documents
14
Period of Report
2023-04-18
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ampe-20230418x8k.htm   iXBRL 8-K 35103
2 EX-99.1 ampe-20230418xex99d1.htm EX-99.1 15864
3 GRAPHIC ampe-20230418xex99d1001.jpg GRAPHIC 10740
  Complete submission text file 0001558370-23-006110.txt   189670

Data Files

Seq Description Document Type Size
4 EX-101.SCH ampe-20230418.xsd EX-101.SCH 3371
5 EX-101.LAB ampe-20230418_lab.xml EX-101.LAB 15363
6 EX-101.PRE ampe-20230418_pre.xml EX-101.PRE 10378
8 EXTRACTED XBRL INSTANCE DOCUMENT ampe-20230418x8k_htm.xml XML 4676
Mailing Address 373 INVERNESS PARKWAY SUITE 200 ENGLEWOOD CO 80112
Business Address 373 INVERNESS PARKWAY SUITE 200 ENGLEWOOD CO 80112 720-437-6500
Ampio Pharmaceuticals, Inc. (Filer) CIK: 0001411906 (see all company filings)

EIN.: 260179592 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35182 | Film No.: 23825607
SIC: 2834 Pharmaceutical Preparations